The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
250
Administered SC
Administered SC
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 56
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 56
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 56
Percent Change from Baseline in Non-High-Density Lipoprotein (HDL) Cholesterol
Time frame: Baseline, Week 56
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)
Time frame: Baseline through Week 56
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Artemis Institute for Clinical Research
Riverside, California, United States
JEM Research Institute
Atlantis, Florida, United States
Headlands Research Orlando
Orlando, Florida, United States
Care Access - Tamarac
Tamarac, Florida, United States
Care Access - Arlington Heights
Arlington Heights, Illinois, United States
L-MARC Research Center
Louisville, Kentucky, United States
IMA Clinical Research Monroe - Armand
Monroe, Louisiana, United States
Pharmasite Research, Inc.
Baltimore, Maryland, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
Clinvest Headlands Llc
Springfield, Missouri, United States
...and 21 more locations